Compare NBTX & BUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | BUR |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | France | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2018 | 2017 |
| Metric | NBTX | BUR |
|---|---|---|
| Price | $51.11 | $4.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $36.00 | $13.58 |
| AVG Volume (30 Days) | 68.3K | ★ 3.0M |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $413,360,000.00 |
| Revenue This Year | $58.17 | $104.62 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.64 | $3.59 |
| 52 Week High | $57.14 | $14.61 |
| Indicator | NBTX | BUR |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 41.56 |
| Support Level | $19.22 | $4.42 |
| Resistance Level | N/A | $4.97 |
| Average True Range (ATR) | 3.29 | 0.27 |
| MACD | 1.71 | 0.04 |
| Stochastic Oscillator | 77.12 | 21.72 |
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.